ClinicalTrials.gg
CompletedNCT00723450Updated Jan 9, 2017Results posted

Lamictal as Add-on Treatment for Bipolar I Disorder in Pediatric Patients

A Phase 3 interventional study of lamictal in Bipolar Disorder, sponsored by GlaxoSmithKline. Completed at 46 sites in United States. Open to participants aged 10 Years to 17 Years. Per ClinicalTrials.gov, last updated 2017-01-09.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
301
Allocation
Randomized
Ages
10 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 33 studies testing lamotrigine in Bipolar Disorder — none open to participants now, none under way, none of them phase 3. Lamotrigine · Bipolar Disorder.

Enrollment
4th of 33
301 · median 72
Started
2008
with 3 others
Phase 3
11 of 33
none open now
Registered
23rd of 33
by date
Lead sponsor
9 of 33
GlaxoSmithKline

Among the 33 studies testing lamotrigine in Bipolar Disorder, this one is the 4th largest by enrollment, is one of 4 that started in 2008, is one of 11 in phase 3, and was the 23rd registered.

Bipolar Disorder

1,685 studies on the registry are indexed under Bipolar Disorder; 268 are open to participants now.

Browse Bipolar Disorder studies →

Open to participants now

None of the 33 studies testing lamotrigine in Bipolar Disorder is open now. The open studies under Bipolar Disorder, anywhere →

About lamotrigine

Lamotrigine: first FDA approval 1994 (LAMICTAL). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 208 Bipolar Disorder studies recruiting now, 59 (28%) set no upper age limit and 136 (65%) stop at 75 or younger; 38 take children under 18; 51 take healthy volunteers.

This study: 10 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 33 studies testing lamotrigine in Bipolar Disorder as a file.
02

Study summary

The study will be a multi-center, parallel, group, placebo control, double-blind, randomized controlled trial of lamictal as add-on maintenance treatment in pediatric outpatients (aged 10 to 17 years) diagnosed with Bipolar I disorder. The study consists of 4 phases: Screen (approximately 2 weeks), Open label phase (up to 18 weeks), Randomized phase (up to 36 weeks) and Taper and follow-up phase (up to 4 weeks).

03

Conditions studied

  • Bipolar Disorder

Browse trials for

Keywords

  • Bipolar I pediatric lamictal adolescent
04

Who can participate

Ages eligible
10 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject is male or female between the ages of 10 and 17 years, inclusive.
  • Subject has a diagnosis of bipolar I disorder and is currently experiencing a manic/hypomanic, depressed, or mixed mood episode
  • Subject is currently receiving a stable treatment regimen.
  • Subject is living with his/her custodial parent(s) or legal guardian(s) and has contact with them on a daily basis.

Exclusion criteria

Exclusion Criteria

  • Subject has been diagnosed with a primary Axis I disorder (with the exception of bipolar I disorder, ADHD, anxiety disorders, oppositional defiant disorder, or conduct disorder) or any Axis II disorder.
  • Subject currently has signs or symptoms of psychosis or a history of psychosis within the previous four weeks.
  • Subject has been diagnosed with epilepsy, autism, Asperger's syndrome, or Tourette's syndrome.
  • Subject has experienced a serious rash, such as Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis, or a rash otherwise requiring hospitalization.
  • Subject has experienced a rash related to prior LAMICTAL use, or for whom LAMICTAL treatment was discontinued for safety reasons.
  • Subject has received any antidepressant medication, or atomoxetine, during the four weeks prior to the Screen Visit.
  • Subject has initiated psychotherapy within 2 months prior to the Screen Visit, or plans to initiate psychotherapy during the trial.
  • Subject in the 10-12 year old age group has a (BMI) less than or equal 15 or greater than or equal to 30; a subject in the 13-17 year old age group has a BMI less than or equal to 17 or greater than or equal to 34.
  • Subject tests positive for illicit drug use at the Screen Visit, has a history of alcohol or substance abuse or dependence (other than nicotine dependence) within the past three months, or has a positive blood alcohol level at the Screen Visit.
  • Subject, in the investigator's judgment, poses a current homicidal or serious suicidal risk, has made a suicide attempt within the twelve months preceding the Screen Visit, has ever been homicidal.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
301 participants (actual)

Study arms

  • Placebo comparator
    placebo

    Placebo Controlled

    Drug: lamictal

  • Experimental
    lamictal

    Flexible Dosing

    Drug: lamictal

Interventions

06

What researchers measure

Primary outcomes

  1. Time From Randomization to the Occurrence of a Bipolar Event (TOBE)

    TOBE was defined by the first prescription of any additional pharmacotherapy to treat bipolar symptoms, increasing the dose(s) of the participants conventional bipolar medication(s), treatment with electroconvulsive therapy, or moving the participant to a more restricted environment for observation, safety, or treatment; or participant withdrawal from the study due to a bipolar-related adverse event (AE) or serious adverse event (SAE); or participants withdrawal from the study due to lack of efficacy as defined by rating scale threshold scores. TOBE was calculated using a log rank test with stratification for index mood state (depression, mania/hypomania, mixed mood).

    Time frame: From randomization until Week 36

Secondary outcomes

  1. Time From Randomization to Withdrawal From the Study for Any Cause (TTW)

    The time from randomization to the withdrawal from study was analyzed. TTW was calculated using the log rank test with stratification for index mood state (depression, mania/hypomania, mixed mood).

    Time frame: From randomization until withdrawal from the study for any cause (up to Week 36)

  2. Time From Randomization to Intervention for a Mood Episode (TIME)

    The time from randomization to the intervention for a mood episode (depression, mania/hypomania or mixed mood) was analyzed. TIME was calculated using the log rank test with stratification for index mood state (depression, mania/hypomania, mixed mood).

    Time frame: From randomization until intervention administered for a mood episode (up to Week 36)

  3. Time From Randomization to Intervention for Depression (TIDep), Mania/Hypomania (TIMan), or a Mixed Episode (TIMix)

    The time from randomization to intervention for depression (TIDep), mania/hypomania (TIMan), or a mixed episode (TIMix) was analyzed. TIDep, TIMan, and TIMix were calculated using the log rank test with stratification for index mood state (depression, mania/hypomania, mixed mood).

    Time frame: From randomization until intervention administered for depression, mania/hypomania or a mixed episode (up to Week 36)

  4. Number of Participants Experiencing a Relapse/Recurrence to Depression, Mania/Hypomania, or Mixed Mood State

    The number of participants requiring intervention to treat either the emergence of or a change in bipolar symptoms that is, experiencing a relapse/recurrence to depression, mania/hypomania, or mixed mood state were analyzed.

    Time frame: From randomization until a relapse/recurrence to depression, mania/hypomania, or mixed mood state (up to Week 36)

  5. Number of Participants Experiencing a Relapse/Recurrence Within the First 30, 90, and 180 Days in the Randomized Phase

    The proportion of participants (par.) requiring intervention to treat either the emergence of or a change in bipolar symptoms, that is, experiencing a relapse/recurrence to depression, mania/hypomania, or mixed mood state at any time within the first 30, 90, and 180 days in the Randomized Phase were analyzed.

    Time frame: From randomization up to Week 36

  6. Change From Baseline in the Quick Inventory of Depressive Symptomatology - Clinician Interview, Semi-structured, Adolescent Version (QIDS- A17-C) at Each Visit in the Open-Label Phase

    The QIDS-A17-C is a 17-item scale used to assess depression severity in adolescents according to the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision (DSM-IV-TR) diagnostic criteria for a major depressive episode; it is a modified version of the Quick Inventory of Depressive Symptomatology (QIDS) used for adults. Each item is scored on a 0-3 scale, yielding 9 domain scores. The range of scores is 0 (best possible outcome) to 27 (worst possible outcome). Analysis was performed using mixed model repeated measures.

    Time frame: Baseline and Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, and 18

  7. Change From Randomization in the Quick Inventory of Depressive Symptomatology - Clinician Interview, Semi-structured, Adolescent Version (QIDS- A17-C) at Each Visit in the Randomized Phase

    The QIDS-A17-C is a 17-item scale used to assess depression severity in adolescents according to the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision (DSM-IV-TR) diagnostic criteria for a major depressive episode; it is a modified version of the Quick Inventory of Depressive Symptomatology (QIDS) used for adults. Each item is scored on a 0-3 scale, yielding 9 domain scores. The range of scores is 0 (best possible outcome) to 27 (worst possible outcome). Analysis was performed using mixed model repeated measures.

    Time frame: Randomization and Weeks 1, 2, 3, 4, 6, 8, 10, 12, 16, 20, 24, 28, 32, and 36

  8. Change From Baseline in the Quick Inventory of Depressive Symptomatology - Self-report Adolescent Version (QIDS-A17-SR) at Each Visit in the Open-Label Phase

    The QIDS-A17-SR is a 17-item scale used to assess depression severity in adolescents according to the DSM-IV-TR diagnostic criteria for a major depressive episode; it is a modified version of the Quick Inventory of Depressive Symptomatology (QIDS) used for adults. Each item is scored on a 0-3 scale, yielding 9 domain scores. The range of scores is 0 (best possible outcome) to 27 (worst possible outcome). The scale is completed by the participant. Analysis was performed using mixed model repeated measures.

    Time frame: Baseline and Weeks 4, 8, 12, 16, and 18

  9. Change From Randomization in the Quick Inventory of Depressive Symptomatology - Self-report Adolescent Version (QIDS-A17-SR) at Each Visit in the Randomized Phase

    The QIDS-A17-SR is a 17-item scale used to assess depression severity in adolescents according to the DSM-IV-TR diagnostic criteria for a major depressive episode; it is a modified version of the Quick Inventory of Depressive Symptomatology (QIDS) used for adults. Each item is scored on a 0-3 scale, yielding 9 domain scores. The range of scores is 0 (best possible outcome) to 27 (worst possible outcome). The scale is completed by the participant. Analysis was performed using mixed model repeated measures.

    Time frame: Randomization and Weeks 8, 16, 24, 32, and 36

  10. Change From Baseline in the Clinical Global Impressions - Bipolar, Severity of Illness (CGI-BP[S]) at Each Visit in the Open-Label Phase

    Severity of the bipolar illness was based on the CGI-BP(S) score which had a range from 1 (normal, not ill) to 7 (very severely ill). Analysis was performed using mixed model repeated measures.

    Time frame: Baseline and Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, and 18

  11. Change From Randomization in the Clinical Global Impressions - Bipolar, Severity of Illness (CGI-BP[S]) at Each Visit in the Randomized Phase

    Severity of the bipolar illness was based on the CGI-BP(S) score which had a range from 1 (normal, not ill) to 7 (very severely ill). Analysis was performed using mixed model repeated measures.

    Time frame: Randomization and Weeks 1, 2, 3, 4, 6, 8, 10, 12, 16, 20, 24, 28, 32, and 36

  12. Summary of Clinical Global Impressions - Bipolar - Improvement of Illness (CGI-BP [I]) Scores During Open-label Phase

    Improvement of bipolar illness was based on the CGI-BP (I) score which ranged from 1 (very much improved) to 7 (very much worse). Analysis was performed using mixed model repeated measures.

    Time frame: Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, and 18

  13. Summary of Clinical Global Impressions - Bipolar - Improvement of Illness (CGI-BP [I]) Scores During Randomized Phase

    Improvement of bipolar illness was based on the CGI-BP(I) score which ranged from 1 (very much improved) to 7 (very much worse). Analysis was performed using mixed model repeated measures.

    Time frame: Randomization weeks 1, 2, 3, 4, 6, 8, 10, 12, 16, 20, 24, 28, 32 and 36

  14. Number of Participants Considered Much Improved or Very Much Improved [Defined as a Clinical Global Impression-Bipolar Version, Improvement of Illness (CGI-BP[I]), Score of 1 or 2] at Each Visit Compared to Baseline in the Open-Label Phase

    The CGI-BP(I) asks the following question: "Compared to the Baseline assessment in this trial, how much has the participant changed?". Scores on the CGI-I range from 1 (very much improved) to 7 (very much worse). The investigator or their designee rated improvement regardless of whether the improvement to be due to drug treatment. Improvement defined as CGI-BP(I)=1 (improved) or 2 (very much improved). Missing data imputed using last-observation carried forward (LOCF).

    Time frame: Baseline and Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, and 18

  15. Number of Participants Considered Much Improved or Very Much Improved [Defined as a Clinical Global Impression-Bipolar Version, Improvement of Illness (CGI-BP[I]), Score of 1 or 2] at Each Visit Compared to Randomization in the Randomized Phase

    The CGI-BP(I) asks the following question: "Compared to the Randomization assessment in this trial, how much has the participant changed?". Scores on the CGI-I range from 1 (very much improved) to 7 (very much worse). The investigator or their designee rated improvement regardless of whether the improvement to be due to drug treatment. Improvement defined as CGI-BP(I)=1 (improved) or 2 (very much improved). Missing data imputed using last-observation carried forward (LOCF).

    Time frame: Randomization and Weeks 1, 2, 3, 4, 6, 8, 10, 12, 16, 20, 24, 28, 32, and 36

  16. Change From Baseline in the Young Mania Rating Scale (YMRS) at Each Visit in the Open-Label Phase

    The YMRS consists of 11 items and is based on the participant's report of their mania symptoms. It is clinician rated. Four items (irritability, speech, thought content, and disruptive/aggressive behavior) are rated on a scale of 0 to 8, while the other seven items (elevated mood, increased motor activity-energy, sexual interest, sleep, language, appearance, and insight) are rated on a scale of 0 to 4. The range of scores for the YMRS is 0 (best possible outcome) to 60 (worst possible outcome). The YMRS was completed by the investigator or their qualified designee. Analysis was performed using mixed model repeated measures.

    Time frame: Baseline and Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, and 18

  17. Change From Randomization in the Young Mania Rating Scale (YMRS) at Each Visit in the Randomized Phase

    The YMRS consists of 11 items and is based on the participant's report of their mania symptoms. It is clinician rated. Four items (irritability, speech, thought content, and disruptive/aggressive behavior) are rated on a scale of 0 to 8, while the other seven items (elevated mood, increased motor activity-energy, sexual interest, sleep, language, appearance, and insight) are rated on a scale of 0 to 4. The range of scores for the YMRS is 0 (best possible outcome) to 60 (worst possible outcome). The YMRS was completed by the investigator or their qualified designee. Analysis was performed using mixed model repeated measures.

    Time frame: Randomization and Weeks 1, 2, 3, 4, 6, 8, 10, 12, 16, 20, 24, 28, 32, and 36

  18. Change From Baseline in the Parent Version of the Young Mania Rating Scale (P-YMRS) at Each Visit in the Open-Label Phase

    The P-YMRS was adapted from the YMRS for completion by parents of the pediatric participants with bipolar disorder in order to assess the severity of the manic symptoms. The P-YMRS consisted of 11 items and had a total score range of 0 (best possible outcome) to 60 (worst possible outcome). The P-YMRS was completed by the participant's custodial parent or legal guardian. Analysis was performed using mixed model repeated measures.

    Time frame: Baseline and Weeks 4, 8, 12, 16, and 18

  19. Change From Randomization in the Parent Version of the Young Mania Rating Scale (P-YMRS) at Each Visit in the Randomized Phase

    The P-YMRS was adapted from the YMRS for completion by parents of the pediatric participants with bipolar disorder in order to assess the severity of the manic symptoms. The P-YMRS consisted of 11 items and had a total score range of 0 (best possible outcome) to 60 (worst possible outcome). The P-YMRS was completed by the participant's custodial parent or legal guardian. Analysis was performed using mixed model repeated measures.

    Time frame: Randomization and Weeks 8, 16, 24, 32, and 36

  20. Change From Baseline in the Conners' Global Index - Parent Version (CGI-P) at Each Visit in the Open-Label Phase

    The CGI-P is a 10-item scale used to assess attention deficit hyperactivity disorder (ADHD) symptoms in children and adolescents aged 3-17 years of age. The scale is composed of two factors: restless-impulsive behavior and emotional lability. Each item was scored on a 0-3 scale. The range of scores for the CGI-P is 0 (best possible outcome) to 30 (worst possible outcome). The CGI-P was completed by the participant's custodial parent or legal guardian. Analysis was performed using mixed model repeated measures.

    Time frame: Baseline and Weeks 4, 8, 12, 16, and 18

  21. Change From Randomization in the Conners' Global Index - Parent Version (CGI-P) at Each Visit in the Randomized Phase.

    The CGI-P is a 10-item scale used to assess attention deficit hyperactivity disorder (ADHD) symptoms in children and adolescents aged 3-17 years of age. The scale is composed of two factors: restless-impulsive behavior and emotional lability. Each item was scored on a 0-3 scale. The range of scores for the CGI-P is 0 (best possible outcome) to 30 (worst possible outcome). The CGI-P was completed by the participant's custodial parent or legal guardian. Analysis was performed using mixed model repeated measures.

    Time frame: Randomization and Weeks 8, 16, 24, 32, and 36

07

Results

Posted Jun 4, 2014

Participant flow

A total of 301 participants were enrolled in the study, of which 298 subjects took at least one dose of lamotrigine (LTG). One hundred and seventy three participants met stabilization criteria and entered the Randomized Phase.

Open-Label Phase
Participant flow — Open-Label Phase
MilestoneLTG: Open-Label PhasePlaceboLamotrigine
Started29800
Completed17300
Not completed12500
Withdrew: Adverse event2600
Withdrew: Lack of efficacy1800
Withdrew: Protocol violation3500
Withdrew: Lost to follow-up700
Withdrew: Physician decision200
Withdrew: Withdrawal by subject3700
Randomized Phase
Participant flow — Randomized Phase
MilestoneLTG: Open-Label PhasePlaceboLamotrigine
Started08687
Completed02120
Not completed06567
Withdrew: Adverse event02617
Withdrew: Lack of efficacy01111
Withdrew: Protocol violation0913
Withdrew: Lost to follow-up023
Withdrew: Physician decision031
Withdrew: Withdrawal by subject01422

Outcome measures

PrimaryTime From Randomization to the Occurrence of a Bipolar Event (TOBE)

TOBE was defined by the first prescription of any additional pharmacotherapy to treat bipolar symptoms, increasing the dose(s) of the participants conventional bipolar medication(s), treatment with electroconvulsive therapy, or moving the participant to a more restricted environment for observation, safety, or treatment; or participant withdrawal from the study due to a bipolar-related adverse event (AE) or serious adverse event (SAE); or participants withdrawal from the study due to lack of efficacy as defined by rating scale threshold scores. TOBE was calculated using a log rank test with stratification for index mood state (depression, mania/hypomania, mixed mood).

Time frame:
From randomization until Week 36
Reported as:
Mean · Days
Time From Randomization to the Occurrence of a Bipolar Event (TOBE)
DaysPlaceboLamotrigine
Stratum: Depression, n=22,2150 ± 3.8155 ± 14.7
Stratum: Mania/Hypomania, n=36, 37120 ± 12.2163 ± 12.2
Stratum: Mixed Mood, n=28, 29107 ± 13.8136 ± 15.4
Statistical analysis
  • Placebo vs Lamotrigine · Log Rank · p = 0.0717A stratified log rank test was performed where the stratification factor was the index mood state at Screen visit.
SecondaryTime From Randomization to Withdrawal From the Study for Any Cause (TTW)

The time from randomization to the withdrawal from study was analyzed. TTW was calculated using the log rank test with stratification for index mood state (depression, mania/hypomania, mixed mood).

Time frame:
From randomization until withdrawal from the study for any cause (up to Week 36)
Reported as:
Mean · Days
Time From Randomization to Withdrawal From the Study for Any Cause (TTW)
DaysPlaceboLamotrigine
Stratum: Depression, n=22, 21113 ± 21.4141 ± 20.0
Stratum: Mania/Hypomania, n=36, 37138 ± 17.3144 ± 15.6
Stratum: Mixed Mood, n=28, 29101 ± 15.7106 ± 16.3
SecondaryTime From Randomization to Intervention for a Mood Episode (TIME)

The time from randomization to the intervention for a mood episode (depression, mania/hypomania or mixed mood) was analyzed. TIME was calculated using the log rank test with stratification for index mood state (depression, mania/hypomania, mixed mood).

Time frame:
From randomization until intervention administered for a mood episode (up to Week 36)
Reported as:
Mean · Days
Time From Randomization to Intervention for a Mood Episode (TIME)
DaysPlaceboLamotrigine
Stratum: Depression, n=22, 2162 ± 5.2164 ± 12.7
Stratum: Mania/Hypomania, n=36, 37129 ± 11.7179 ± 10.8
Stratum: Mixed Mood, n=28, 29120 ± 13.7127 ± 12.0
SecondaryTime From Randomization to Intervention for Depression (TIDep), Mania/Hypomania (TIMan), or a Mixed Episode (TIMix)

The time from randomization to intervention for depression (TIDep), mania/hypomania (TIMan), or a mixed episode (TIMix) was analyzed. TIDep, TIMan, and TIMix were calculated using the log rank test with stratification for index mood state (depression, mania/hypomania, mixed mood).

Time frame:
From randomization until intervention administered for depression, mania/hypomania or a mixed episode (up to Week 36)
Reported as:
Mean · Days
Time From Randomization to Intervention for Depression (TIDep), Mania/Hypomania (TIMan), or a Mixed Episode (TIMix)
DaysPlaceboLamotrigine
TIDep: Depression, n=22, 2161 ± 1.546 ± 1.5
TIDep: Mania/Hypomania, n=36, 37NA ± NANA ± NA
TIDep: Mixed Mood, n=28, 2959 ± 2.6159 ± NA
TIMan: Depression, n=22, 2174 ± 3.9182 ± NA
TIMan: Mania/Hypomania, n=36, 37139 ± 11.561 ± 2.1
TIMan: Mixed Mood, n=28, 29105 ± 7.3148 ± 8.5
TIMix: Depression, n=22, 2137 ± 1.3158 ± NA
TIMix: Mania/Hypomania, n=36, 37135 ± 6.3194 ± 7.5
TIMix: Mixed Mood, n=28, 29160 ± 10.757 ± 2.5
SecondaryNumber of Participants Experiencing a Relapse/Recurrence to Depression, Mania/Hypomania, or Mixed Mood State

The number of participants requiring intervention to treat either the emergence of or a change in bipolar symptoms that is, experiencing a relapse/recurrence to depression, mania/hypomania, or mixed mood state were analyzed.

Time frame:
From randomization until a relapse/recurrence to depression, mania/hypomania, or mixed mood state (up to Week 36)
Reported as:
Number · Participants
Number of Participants Experiencing a Relapse/Recurrence to Depression, Mania/Hypomania, or Mixed Mood State
ParticipantsPlaceboLamotrigine
Depression53
Mania/hypomania166
Mixed episode state109
SecondaryNumber of Participants Experiencing a Relapse/Recurrence Within the First 30, 90, and 180 Days in the Randomized Phase

The proportion of participants (par.) requiring intervention to treat either the emergence of or a change in bipolar symptoms, that is, experiencing a relapse/recurrence to depression, mania/hypomania, or mixed mood state at any time within the first 30, 90, and 180 days in the Randomized Phase were analyzed.

Time frame:
From randomization up to Week 36
Reported as:
Number · Participants
Number of Participants Experiencing a Relapse/Recurrence Within the First 30, 90, and 180 Days in the Randomized Phase
ParticipantsPlaceboLamotrigine
Mania/hypomania, 30 days, n=16, 692
Mania/hypomania, 90 days, n=16, 6124
Mania/hypomania, 180 days, n=16, 6165
Depression, 30 days, n=5, 311
Depression, 90 days, n=5, 352
Depression, 180 days, n=5, 353
Mixed mood state, 30 days, n= 10, 932
Mixed mood state, 90 days, n= 10, 976
Mixed mood state, 180 days, n= 10, 9108
SecondaryChange From Baseline in the Quick Inventory of Depressive Symptomatology - Clinician Interview, Semi-structured, Adolescent Version (QIDS- A17-C) at Each Visit in the Open-Label Phase

The QIDS-A17-C is a 17-item scale used to assess depression severity in adolescents according to the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision (DSM-IV-TR) diagnostic criteria for a major depressive episode; it is a modified version of the Quick Inventory of Depressive Symptomatology (QIDS) used for adults. Each item is scored on a 0-3 scale, yielding 9 domain scores. The range of scores is 0 (best possible outcome) to 27 (worst possible outcome). Analysis was performed using mixed model repeated measures.

Time frame:
Baseline and Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, and 18
Reported as:
Least squares mean · Scores on a Scale
Change From Baseline in the Quick Inventory of Depressive Symptomatology - Clinician Interview, Semi-structured, Adolescent Version (QIDS- A17-C) at Each Visit in the Open-Label Phase
Scores on a ScaleLTG: Open-Label Phase
Week 1-2.1 ± 0.22
Week 2-2.9 ± 0.28
Week 3-3.7 ± 0.28
Week 4-3.8 ± 0.30
Week 5-4.3 ± 0.30
Week 6-4.7 ± 0.30
Week 7-5.1 ± 0.30
Week 8-4.9 ± 0.31
Week 9-5.6 ± 0.30
Week 10-6.1 ± 0.29
Week 11-6.4 ± 0.30
Week 12-6.6 ± 0.32
Week 13-6.7 ± 0.32
Week 14-6.8 ± 0.34
Week 15-6.8 ± 0.40
Week 16-6.8 ± 0.41
Week 17-6.5 ± 0.53
Week 18-6.5 ± 0.70
SecondaryChange From Randomization in the Quick Inventory of Depressive Symptomatology - Clinician Interview, Semi-structured, Adolescent Version (QIDS- A17-C) at Each Visit in the Randomized Phase

The QIDS-A17-C is a 17-item scale used to assess depression severity in adolescents according to the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision (DSM-IV-TR) diagnostic criteria for a major depressive episode; it is a modified version of the Quick Inventory of Depressive Symptomatology (QIDS) used for adults. Each item is scored on a 0-3 scale, yielding 9 domain scores. The range of scores is 0 (best possible outcome) to 27 (worst possible outcome). Analysis was performed using mixed model repeated measures.

Time frame:
Randomization and Weeks 1, 2, 3, 4, 6, 8, 10, 12, 16, 20, 24, 28, 32, and 36
Reported as:
Least squares mean · Scores on a scale
Change From Randomization in the Quick Inventory of Depressive Symptomatology - Clinician Interview, Semi-structured, Adolescent Version (QIDS- A17-C) at Each Visit in the Randomized Phase
Scores on a scalePlaceboLamotrigine
Week 10.8 ± 0.300.5 ± 0.31
Week 21.5 ± 0.371.1 ± 0.37
Week 31.3 ± 0.360.6 ± 0.36
Week 41.2 ± 0.391.0 ± 0.39
Week 61.9 ± 0.491.5 ± 0.47
Week 81.9 ± 0.471.7 ± 0.45
Week 101.4 ± 0.441.5 ± 0.41
Week 121.4 ± 0.401.2 ± 0.39
Week 162.2 ± 0.481.8 ± 0.47
Week 201.5 ± 0.502.5 ± 0.46
Week 241.7 ± 0.531.8 ± 0.51
Week 281.6 ± 0.612.3 ± 0.57
Week 321.0 ± 0.721.9 ± 0.72
Week 362.3 ± 0.631.9 ± 0.63
SecondaryChange From Baseline in the Quick Inventory of Depressive Symptomatology - Self-report Adolescent Version (QIDS-A17-SR) at Each Visit in the Open-Label Phase

The QIDS-A17-SR is a 17-item scale used to assess depression severity in adolescents according to the DSM-IV-TR diagnostic criteria for a major depressive episode; it is a modified version of the Quick Inventory of Depressive Symptomatology (QIDS) used for adults. Each item is scored on a 0-3 scale, yielding 9 domain scores. The range of scores is 0 (best possible outcome) to 27 (worst possible outcome). The scale is completed by the participant. Analysis was performed using mixed model repeated measures.

Time frame:
Baseline and Weeks 4, 8, 12, 16, and 18
Reported as:
Least squares mean · Scores on a scale
Change From Baseline in the Quick Inventory of Depressive Symptomatology - Self-report Adolescent Version (QIDS-A17-SR) at Each Visit in the Open-Label Phase
Scores on a scaleLTG: Open-Label Phase
Week 4-2.7 ± 0.25
Week 8-3.3 ± 0.27
Week 12-4.3 ± 0.28
Week 16-4.5 ± 0.33
Week 18-5.0 ± 0.52
SecondaryChange From Randomization in the Quick Inventory of Depressive Symptomatology - Self-report Adolescent Version (QIDS-A17-SR) at Each Visit in the Randomized Phase

The QIDS-A17-SR is a 17-item scale used to assess depression severity in adolescents according to the DSM-IV-TR diagnostic criteria for a major depressive episode; it is a modified version of the Quick Inventory of Depressive Symptomatology (QIDS) used for adults. Each item is scored on a 0-3 scale, yielding 9 domain scores. The range of scores is 0 (best possible outcome) to 27 (worst possible outcome). The scale is completed by the participant. Analysis was performed using mixed model repeated measures.

Time frame:
Randomization and Weeks 8, 16, 24, 32, and 36
Reported as:
Least squares mean · Scores on a scale
Change From Randomization in the Quick Inventory of Depressive Symptomatology - Self-report Adolescent Version (QIDS-A17-SR) at Each Visit in the Randomized Phase
Scores on a scalePlaceboLamotrigine
Week 81.6 ± 0.471.2 ± 0.48
Week 161.6 ± 0.601.4 ± 0.58
Week 241.0 ± 0.601.5 ± 0.56
Week 320.6 ± 0.660.2 ± 0.63
Week 360.9 ± 0.660.8 ± 0.68
SecondaryChange From Baseline in the Clinical Global Impressions - Bipolar, Severity of Illness (CGI-BP[S]) at Each Visit in the Open-Label Phase

Severity of the bipolar illness was based on the CGI-BP(S) score which had a range from 1 (normal, not ill) to 7 (very severely ill). Analysis was performed using mixed model repeated measures.

Time frame:
Baseline and Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, and 18
Reported as:
Least squares mean · Scores on a scale
Change From Baseline in the Clinical Global Impressions - Bipolar, Severity of Illness (CGI-BP[S]) at Each Visit in the Open-Label Phase
Scores on a scaleLTG: Open-Label Phase
Week 1-0.4 ± 0.05
Week 2-0.6 ± 0.05
Week 3-0.9 ± 0.06
Week 4-1.0 ± 0.06
Week 5-1.2 ± 0.06
Week 6-1.3 ± 0.06
Week 7-1.4 ± 0.07
Week 8-1.5 ± 0.07
Week 9-1.6 ± 0.07
Week 10-1.8 ± 0.07
Week 11-1.9 ± 0.07
Week 12-2.1 ± 0.07
Week 13-2.1 ± 0.07
Week 14-2.1 ± 0.07
Week 15-2.1 ± 0.08
Week 16-2.1 ± 0.10
Week 17-2.0 ± 0.12
Week 18-2.1 ± 0.15
SecondaryChange From Randomization in the Clinical Global Impressions - Bipolar, Severity of Illness (CGI-BP[S]) at Each Visit in the Randomized Phase

Severity of the bipolar illness was based on the CGI-BP(S) score which had a range from 1 (normal, not ill) to 7 (very severely ill). Analysis was performed using mixed model repeated measures.

Time frame:
Randomization and Weeks 1, 2, 3, 4, 6, 8, 10, 12, 16, 20, 24, 28, 32, and 36
Reported as:
Least squares mean · Scores on a scale
Change From Randomization in the Clinical Global Impressions - Bipolar, Severity of Illness (CGI-BP[S]) at Each Visit in the Randomized Phase
Scores on a scalePlaceboLamotrigine
Week 10.2 ± 0.090.0 ± 0.09
Week 20.4 ± 0.120.2 ± 0.12
Week 30.4 ± 0.120.2 ± 0.12
Week 40.6 ± 0.130.3 ± 0.13
Week 60.8 ± 0.150.4 ± 0.15
Week 80.7 ± 0.150.4 ± 0.14
Week 100.4 ± 0.130.6 ± 0.13
Week 120.5 ± 0.140.4 ± 0.14
Week 160.6 ± 0.170.6 ± 0.15
Week 200.5 ± 0.170.8 ± 0.16
Week 240.4 ± 0.170.6 ± 0.16
Week 280.3 ± 0.170.5 ± 0.16
Week 320.2 ± 0.190.5 ± 0.20
Week 360.4 ± 0.190.3 ± 0.21
SecondarySummary of Clinical Global Impressions - Bipolar - Improvement of Illness (CGI-BP [I]) Scores During Open-label Phase

Improvement of bipolar illness was based on the CGI-BP (I) score which ranged from 1 (very much improved) to 7 (very much worse). Analysis was performed using mixed model repeated measures.

Time frame:
Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, and 18
Reported as:
Mean · Scores on a scale
Summary of Clinical Global Impressions - Bipolar - Improvement of Illness (CGI-BP [I]) Scores During Open-label Phase
Scores on a scaleLTG: Open-Label Phase
Week 1, n=2903.6 ± 0.80
Week 2, n=2783.3 ± 0.90
Week 3, n=2703.1 ± 0.96
Week 4, n=2653.0 ± 1.03
Week 5, n=2582.8 ± 1.01
Week 6, n=2432.7 ± 1.05
Week 7, n=2462.5 ± 1.07
Week 8, n=2362.5 ± 1.09
Week 9, n=2272.3 ± 1.05
Week 10, n=2052.2 ± 1.09
Week 11, n=1812.2 ± 0.92
Week 12, n=1682.0 ± 0.87
Week 13, n=1411.9 ± 0.85
Week 14, n=1181.9 ± 0.69
Week 15, n=931.8 ± 0.71
Week 16, n=722.0 ± 0.89
Week 17, n=422.0 ± 0.70
Week 18, n=282.0 ± 0.88
SecondarySummary of Clinical Global Impressions - Bipolar - Improvement of Illness (CGI-BP [I]) Scores During Randomized Phase

Improvement of bipolar illness was based on the CGI-BP(I) score which ranged from 1 (very much improved) to 7 (very much worse). Analysis was performed using mixed model repeated measures.

Time frame:
Randomization weeks 1, 2, 3, 4, 6, 8, 10, 12, 16, 20, 24, 28, 32 and 36
Reported as:
Mean · Scores on a scale
Summary of Clinical Global Impressions - Bipolar - Improvement of Illness (CGI-BP [I]) Scores During Randomized Phase
Scores on a scalePlaceboLamotrigine
Week 1, n=84, 853.3 ± 1.403.3 ± 1.37
Week 2, n=82, 813.7 ± 1.483.6 ± 1.38
Week 3, n=74, 753.6 ± 1.393.6 ± 1.34
Week 4, n=65, 703.6 ± 1.513.6 ± 1.35
Week 6, n=58, 643.8 ± 1.643.4 ± 1.49
Week 8, n=51, 603.5 ± 1.723.6 ± 1.47
Week 10, n=45, 553.3 ± 1.643.8 ± 1.19
Week 12, n=45, 493.3 ± 1.523.4 ± 1.29
Week 16, n=43, 503.4 ± 1.733.5 ± 1.37
Week 20, n=37, 433.0 ± 1.483.8 ± 1.36
Week 24, n=34, 363.0 ± 1.593.4 ± 1.44
Week 28, n=29, 322.7 ± 1.563.5 ± 1.44
Week 32, n=28, 273.0 ± 1.633.5 ± 1.28
Week 36, n=27, 243.0 ± 1.683.6 ± 1.10
SecondaryNumber of Participants Considered Much Improved or Very Much Improved [Defined as a Clinical Global Impression-Bipolar Version, Improvement of Illness (CGI-BP[I]), Score of 1 or 2] at Each Visit Compared to Baseline in the Open-Label Phase

The CGI-BP(I) asks the following question: "Compared to the Baseline assessment in this trial, how much has the participant changed?". Scores on the CGI-I range from 1 (very much improved) to 7 (very much worse). The investigator or their designee rated improvement regardless of whether the improvement to be due to drug treatment. Improvement defined as CGI-BP(I)=1 (improved) or 2 (very much improved). Missing data imputed using last-observation carried forward (LOCF).

Time frame:
Baseline and Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, and 18
Reported as:
Number · Participants
Number of Participants Considered Much Improved or Very Much Improved [Defined as a Clinical Global Impression-Bipolar Version, Improvement of Illness (CGI-BP[I]), Score of 1 or 2] at Each Visit Compared to Baseline in the Open-Label Phase
ParticipantsLTG: Open-Label Phase
Week 1, n=29727
Week 2, n=29746
Week 3, n=29772
Week 4, n=29786
Week 5, n=297113
Week 6, n=297124
Week 7, n=297138
Week 8, n=297140
Week 9, n=297159
Week 10, n=297176
Week 11, n=297182
Week 12, n=297195
Week 13, n=297205
Week 14, n=297211
Week 15, n=297210
Week 16, n=297209
Week 17, n=297208
Week 18, n=297206
SecondaryNumber of Participants Considered Much Improved or Very Much Improved [Defined as a Clinical Global Impression-Bipolar Version, Improvement of Illness (CGI-BP[I]), Score of 1 or 2] at Each Visit Compared to Randomization in the Randomized Phase

The CGI-BP(I) asks the following question: "Compared to the Randomization assessment in this trial, how much has the participant changed?". Scores on the CGI-I range from 1 (very much improved) to 7 (very much worse). The investigator or their designee rated improvement regardless of whether the improvement to be due to drug treatment. Improvement defined as CGI-BP(I)=1 (improved) or 2 (very much improved). Missing data imputed using last-observation carried forward (LOCF).

Time frame:
Randomization and Weeks 1, 2, 3, 4, 6, 8, 10, 12, 16, 20, 24, 28, 32, and 36
Reported as:
Number · Participants
Number of Participants Considered Much Improved or Very Much Improved [Defined as a Clinical Global Impression-Bipolar Version, Improvement of Illness (CGI-BP[I]), Score of 1 or 2] at Each Visit Compared to Randomization in the Randomized Phase
ParticipantsPlaceboLamotrigine
Week 13131
Week 22522
Week 32421
Week 42219
Week 62023
Week 82219
Week 102212
Week 122117
Week 162116
Week 202114
Week 242115
Week 282215
Week 321915
Week 362013
SecondaryChange From Baseline in the Young Mania Rating Scale (YMRS) at Each Visit in the Open-Label Phase

The YMRS consists of 11 items and is based on the participant's report of their mania symptoms. It is clinician rated. Four items (irritability, speech, thought content, and disruptive/aggressive behavior) are rated on a scale of 0 to 8, while the other seven items (elevated mood, increased motor activity-energy, sexual interest, sleep, language, appearance, and insight) are rated on a scale of 0 to 4. The range of scores for the YMRS is 0 (best possible outcome) to 60 (worst possible outcome). The YMRS was completed by the investigator or their qualified designee. Analysis was performed using mixed model repeated measures.

Time frame:
Baseline and Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, and 18
Reported as:
Least squares mean · Scores on a scale
Change From Baseline in the Young Mania Rating Scale (YMRS) at Each Visit in the Open-Label Phase
Scores on a scaleLTG: Open-Label Phase
Week 1-3.2 ± 0.39
Week 2-4.8 ± 0.42
Week 3-6.4 ± 0.45
Week 4-6.5 ± 0.46
Week 5-7.5 ± 0.50
Week 6-8.4 ± 0.50
Week 7-9.1 ± 0.51
Week 8-8.8 ± 0.48
Week 9-9.6 ± 0.48
Week 10-10.3 ± 0.49
Week 11-11.1 ± 0.48
Week 12-11.6 ± 0.53
Week 13-12.0 ± 0.58
Week 14-12.0 ± 0.59
Week 15-12.4 ± 0.63
Week 16-12.3 ± 0.78
Week 17-12.2 ± 0.88
Week 18-12.1 ± 1.43
SecondaryChange From Randomization in the Young Mania Rating Scale (YMRS) at Each Visit in the Randomized Phase

The YMRS consists of 11 items and is based on the participant's report of their mania symptoms. It is clinician rated. Four items (irritability, speech, thought content, and disruptive/aggressive behavior) are rated on a scale of 0 to 8, while the other seven items (elevated mood, increased motor activity-energy, sexual interest, sleep, language, appearance, and insight) are rated on a scale of 0 to 4. The range of scores for the YMRS is 0 (best possible outcome) to 60 (worst possible outcome). The YMRS was completed by the investigator or their qualified designee. Analysis was performed using mixed model repeated measures.

Time frame:
Randomization and Weeks 1, 2, 3, 4, 6, 8, 10, 12, 16, 20, 24, 28, 32, and 36
Reported as:
Least squares mean · Scores on a scale
Change From Randomization in the Young Mania Rating Scale (YMRS) at Each Visit in the Randomized Phase
Scores on a scalePlaceboLamotrigine
Week 11.3 ± 0.570.4 ± 0.59
Week 22.6 ± 0.722.1 ± 0.72
Week 32.6 ± 0.691.3 ± 0.71
Week 43.7 ± 0.852.0 ± 0.84
Week 64.9 ± 0.962.3 ± 0.93
Week 84.3 ± 0.983.5 ± 0.93
Week 103.5 ± 0.872.9 ± 0.82
Week 123.2 ± 0.841.6 ± 0.81
Week 164.7 ± 0.933.0 ± 0.89
Week 204.8 ± 0.994.5 ± 0.92
Week 244.2 ± 1.062.9 ± 1.02
Week 284.4 ± 1.043.7 ± 1.01
Week 324.5 ± 1.102.6 ± 1.14
Week 363.5 ± 0.921.2 ± 0.95
SecondaryChange From Baseline in the Parent Version of the Young Mania Rating Scale (P-YMRS) at Each Visit in the Open-Label Phase

The P-YMRS was adapted from the YMRS for completion by parents of the pediatric participants with bipolar disorder in order to assess the severity of the manic symptoms. The P-YMRS consisted of 11 items and had a total score range of 0 (best possible outcome) to 60 (worst possible outcome). The P-YMRS was completed by the participant's custodial parent or legal guardian. Analysis was performed using mixed model repeated measures.

Time frame:
Baseline and Weeks 4, 8, 12, 16, and 18
Reported as:
Least squares mean · Scores on a scale
Change From Baseline in the Parent Version of the Young Mania Rating Scale (P-YMRS) at Each Visit in the Open-Label Phase
Scores on a scaleLTG: Open-Label Phase
Week 4-4.7 ± 0.57
Week 8-6.0 ± 0.62
Week 12-7.4 ± 0.62
Week 16-8.2 ± 0.72
Week 18-9.3 ± 1.29
SecondaryChange From Randomization in the Parent Version of the Young Mania Rating Scale (P-YMRS) at Each Visit in the Randomized Phase

The P-YMRS was adapted from the YMRS for completion by parents of the pediatric participants with bipolar disorder in order to assess the severity of the manic symptoms. The P-YMRS consisted of 11 items and had a total score range of 0 (best possible outcome) to 60 (worst possible outcome). The P-YMRS was completed by the participant's custodial parent or legal guardian. Analysis was performed using mixed model repeated measures.

Time frame:
Randomization and Weeks 8, 16, 24, 32, and 36
Reported as:
Least squares mean · Scores on a scale
Change From Randomization in the Parent Version of the Young Mania Rating Scale (P-YMRS) at Each Visit in the Randomized Phase
Scores on a scalePlaceboLamotrigine
Week 84.9 ± 0.934.3 ± 0.95
Week 162.7 ± 1.132.6 ± 1.09
Week 245.3 ± 1.355.7 ± 1.29
Week 325.1 ± 1.336.0 ± 1.32
Week 365.3 ± 1.334.5 ± 1.36
SecondaryChange From Baseline in the Conners' Global Index - Parent Version (CGI-P) at Each Visit in the Open-Label Phase

The CGI-P is a 10-item scale used to assess attention deficit hyperactivity disorder (ADHD) symptoms in children and adolescents aged 3-17 years of age. The scale is composed of two factors: restless-impulsive behavior and emotional lability. Each item was scored on a 0-3 scale. The range of scores for the CGI-P is 0 (best possible outcome) to 30 (worst possible outcome). The CGI-P was completed by the participant's custodial parent or legal guardian. Analysis was performed using mixed model repeated measures.

Time frame:
Baseline and Weeks 4, 8, 12, 16, and 18
Reported as:
Least squares mean · Scores on a scale
Change From Baseline in the Conners' Global Index - Parent Version (CGI-P) at Each Visit in the Open-Label Phase
Scores on a scaleLTG: Open-Label Phase
Week 4-4.0 ± 0.36
Week 8-5.7 ± 0.43
Week 12-6.7 ± 0.47
Week 16-7.1 ± 0.56
Week 18-8.2 ± 1.07
SecondaryChange From Randomization in the Conners' Global Index - Parent Version (CGI-P) at Each Visit in the Randomized Phase.

The CGI-P is a 10-item scale used to assess attention deficit hyperactivity disorder (ADHD) symptoms in children and adolescents aged 3-17 years of age. The scale is composed of two factors: restless-impulsive behavior and emotional lability. Each item was scored on a 0-3 scale. The range of scores for the CGI-P is 0 (best possible outcome) to 30 (worst possible outcome). The CGI-P was completed by the participant's custodial parent or legal guardian. Analysis was performed using mixed model repeated measures.

Time frame:
Randomization and Weeks 8, 16, 24, 32, and 36
Reported as:
Least squares mean · Scores on a scale
Change From Randomization in the Conners' Global Index - Parent Version (CGI-P) at Each Visit in the Randomized Phase.
Scores on a scalePlaceboLamotrigine
Week 83.1 ± 0.752.1 ± 0.77
Week 163.4 ± 0.921.2 ± 0.90
Week 242.4 ± 1.123.1 ± 1.05
Week 322.7 ± 1.102.6 ± 1.08
Week 361.5 ± 1.000.5 ± 1.03

Adverse events

Collected over On-treatment serious adverse events (SAEs) and non-serious adverse events (AEs) were collected from the first dose of investigational product until the last visit of the Open-Label or Double-Blind Taper and Follow-up Phase (up to Taper Week 4).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Open-Label and Open-Label Taper Phases: LTG—19/298 (6.4%)177/298 (59.4%)
Randomized and Double-blind Taper Phases: Placebo—5/86 (5.8%)41/86 (47.7%)
Randomized and Double-blind Taper Phases: LTG—1/87 (1.1%)45/87 (51.7%)
Most frequent serious events
Showing 10 of 18
Most frequent serious events
EventOpen-Label and Open-Label Taper Phases: LTGRandomized and Double-blind Taper Phases: PlaceboRandomized and Double-blind Taper Phases: LTG
Suicidal ideationPsychiatric disorders5/2981/860/87
ManiaPsychiatric disorders3/2981/860/87
Bipolar I disorderPsychiatric disorders1/2981/860/87
Infectious mononucleosisInfections and infestations0/2981/860/87
Urinary tract infectionInfections and infestations0/2981/860/87
Intentional overdoseInjury, poisoning and procedural complications0/2981/860/87
Emotional disorderPsychiatric disorders0/2980/861/87
AgitationPsychiatric disorders3/2980/860/87
IrritabilityGeneral disorders2/2980/860/87
AggressionPsychiatric disorders1/2980/860/87
Most frequent other events
Showing 10 of 17
Most frequent other events
EventOpen-Label and Open-Label Taper Phases: LTGRandomized and Double-blind Taper Phases: PlaceboRandomized and Double-blind Taper Phases: LTG
HeadacheNervous system disorders106/29818/8618/87
IrritabilityGeneral disorders16/29814/867/87
Abdominal pain upperGastrointestinal disorders47/2983/865/87
NauseaGastrointestinal disorders39/2980/860/87
Oropharyngeal painRespiratory, thoracic and mediastinal disorders30/2982/867/87
VomitingGastrointestinal disorders25/2983/865/87
NasopharyngitisInfections and infestations25/2985/867/87
DizzinessNervous system disorders24/2980/860/87
InfluenzaInfections and infestations0/2982/867/87
CoughRespiratory, thoracic and mediastinal disorders21/2984/867/87

Baseline characteristics

Age, Continuous
Age, Continuous(Years)PlaceboLamotrigineTotal
Mean13.5 ± 2.2213.4 ± 2.3313.5 ± 2.27
Gender
Gender(Participants)PlaceboLamotrigineTotal
Female393372
Male4754101
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboLamotrigineTotal
African American/African Heritage9918
American Indian or Alaska Native011
Asian - East Asian Heritage101
White - Arabic/North African Heritage101
White - White/Caucasian/European Heritage7171142
Mixed Race4610
08

Study locations

46 sites
  • GSK Investigational Site
    Dothan, Alabama 36305, United States
  • GSK Investigational Site
    Scottsdale, Arizona 85252, United States
  • GSK Investigational Site
    San Diego, California 92108, United States
  • GSK Investigational Site
    Stanford, California 94304, United States
  • GSK Investigational Site
    Washington, District of Columbia 20010, United States
  • GSK Investigational Site
    Bradenton, Florida 34201, United States
  • GSK Investigational Site
    Gainesville, Florida 32607, United States
  • GSK Investigational Site
    Jacksonville, Florida 32216, United States
  • GSK Investigational Site
    Orlando, Florida 32839, United States
  • GSK Investigational Site
    Tampa, Florida 33613, United States
  • GSK Investigational Site
    Winter Park, Florida 32789, United States
  • GSK Investigational Site
    Smyrna, Georgia 30080, United States
  • GSK Investigational Site
    Libertyville, Illinois 60048, United States
  • GSK Investigational Site
    Naperville, Illinois 60563, United States
  • GSK Investigational Site
    Indianapolis, Indiana 46202, United States
  • GSK Investigational Site
    Overland Park, Kansas 66211, United States
  • GSK Investigational Site
    Wichita, Kansas 67206, United States
  • GSK Investigational Site
    Shreveport, Louisiana 71103, United States
  • GSK Investigational Site
    Baltimore, Maryland 21208, United States
  • GSK Investigational Site
    Boston, Massachusetts 02114, United States
  • GSK Investigational Site
    Boston, Massachusetts 02115, United States
  • GSK Investigational Site
    Springfield, Massachusetts 01199, United States
  • GSK Investigational Site
    Worcester, Massachusetts 01655, United States
  • GSK Investigational Site
    Rochester, Minnesota 55905, United States
  • GSK Investigational Site
    St. Charles, Missouri 63304, United States
  • GSK Investigational Site
    Lincoln, Nebraska 68526, United States
  • GSK Investigational Site
    Piscataway, New Jersey 08854, United States
  • GSK Investigational Site
    Albuquerque, New Mexico 87109, United States
  • GSK Investigational Site
    Mount Kisco, New York 10549, United States
  • GSK Investigational Site
    Stony Brook, New York 11794-8790, United States
  • GSK Investigational Site
    Chapel Hill, North Carolina 27517, United States
  • GSK Investigational Site
    Fargo, North Dakota 58104, United States
  • GSK Investigational Site
    Cincinnati, Ohio 45219, United States
  • GSK Investigational Site
    Cincinnati, Ohio 45229, United States
  • GSK Investigational Site
    Cleveland, Ohio 44106, United States
  • GSK Investigational Site
    Columbus, Ohio 43210, United States
  • GSK Investigational Site
    Toledo, Ohio 43609, United States
  • GSK Investigational Site
    Philadelphia, Pennsylvania 19104, United States
  • GSK Investigational Site
    Dallas, Texas 75235, United States
  • GSK Investigational Site
    Houston, Texas 77007, United States
  • GSK Investigational Site
    Houston, Texas 77008, United States
  • GSK Investigational Site
    Houston, Texas 77030, United States
  • GSK Investigational Site
    Salt Lake City, Utah 84105, United States
  • GSK Investigational Site
    Roanoke, Virginia 24013, United States
  • GSK Investigational Site
    Kirkland, Washington 98033, United States
  • GSK Investigational Site
    Seattle, Washington 98105, United States
09

References and documents

Publications

  • Findling RL, Chang K, Robb A, Foster VJ, Horrigan J, Krishen A, Wamil A, Kraus JE, DelBello M. Adjunctive Maintenance Lamotrigine for Pediatric Bipolar I Disorder: A Placebo-Controlled, Randomized Withdrawal Study. J Am Acad Child Adolesc Psychiatry. 2015 Dec;54(12):1020-1031.e3. doi: 10.1016/j.jaac.2015.09.017. Epub 2015 Oct 14. PubMed 26598477 ↗

Individual participant data

Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2008, a primary completion of Aug 2013 and a completion of Aug 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2014, 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 24, 2008
First posted
Jul 28, 2008
Start
Jul 2008
Primary completionActual
Aug 2013
CompletionActual
Aug 2013
Results first posted
Jun 4, 2014
Last update
Jan 9, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 9, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00723450
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Jul 28, 2008
Start date
Jul 2008
Primary completion
Aug 2013
Completion
Aug 2013
Results posted
Jun 4, 2014
Last update
Jan 9, 2017

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lamotrigine

Start the discussion